Previous 10 | Next 10 |
Baudax Bio ( NASDAQ: BXRX ) added ~70% pre-market Tuesday after announcing a positive outcome in its first interim analysis for Phase 2 trial for experimental neuromuscular blocking agent BX1000 in patients undergoing elective surgery. The trial is designed to evaluate the neuromu...
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (...
Baudax Bio ( NASDAQ: BXRX ) said in a Dec. 30, 2022 SEC filing that it eliminated its commercial personnel for its first commercial product, pain drug Anjeso (IV meloxicam). The company added that on Dec. 28, 2022, the discontinuation of sale of Anjeso was acknowledged b...
Palm Beach, FL – December 30, 2022 – FinancialNewsMedia.com News Commentary – According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million people. The global rheumatoid arthritis drugs market is ...
3 Tips and Tricks For Managing Risk With Penny Stocks Risk management is an essential component of penny stock trading, as these stocks are often volatile and unpredictable. Proper risk management helps to minimize potential losses by setting strict limits on the amount of money that can be l...
Are Cheap Stocks Worth The Risk? Whether you call them penny stocks or simply “cheap stocks,” lower-priced company shares present a unique situation for traders. Ever since the introduction of low- and no-fee trading platforms like Robinhood, retail traders have found a place in...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: vaalaa / Shutterstock.com Boeing (NYSE: BA ) stock fans will want to keep an eye on the company when Dec. 13 rolls around as it has a “historic announcement” to make. Boeing is set to make ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Baudax Bio (NASDAQ: BXRX ) stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000. BX1000 is the company’s drug candidate fo...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com The trading week is almost done but we’ve still got the biggest pre-market stock movers to go over for Friday! Moving stocks this morning are clinical trials, public offerings, e...
Baudax Bio ( NASDAQ: BXRX ) said it started a phase 2 trial to evaluate the safety tolerability and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. The study will test BX1000 in about 80 adult patients, 18-65 years of ...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023